Biotech Industry Examiner’s Post

Take a look at our latest publication: "Architectural Organization and Molecular Profiling of 3D Cancer Heterospheroids and Their Application in Drug Testing" Our study explores the development of our multicellular tumor heterospheroids aka BioSPHEERs. These spheroids more accurately mimic the complex architecture and microenvironment of solid tumors, opening new possibilities in drug testing and reducing reliance on animal models. Our findings underscore the potential of 3D heterospheroids as a robust platform for cancer research and drug discovery, providing more reliable data for evaluating therapeutic strategies. Read more about our approach: https://lnkd.in/d_MMvBXn Contact us to hear how we can assist your cancer research: https://lnkd.in/dRNwu3Gy #CancerResearch #CellModels #DrugDiscovery #Oncology #Innovation #BioneerAS

https://lnkd.in/dGPxU8_T 🔬 Exciting News Alert! 🎉 Thrilled to share that our latest research article in Molecular Cancer: We identified a novel lncRNA transcript, upregulated in NRAS/MAPK-dependent melanoma, and named it T-RECS (yes!). Our findings demonstrate that T-RECS inhibition with antisense oligonucleotides (ASOs) effectively reduces melanoma cell growth and induces apoptosis, with minimal impact on normal melanocytes. Moreover, our preclinical studies show promising results in suppressing tumor growth without toxicity. #MelanomaResearch #cancertreatment

Innovations in Oncology: The Role of 3D-Printed Tumor Models by Carcinotech   Carcinotech is leading advancements in oncology research through the development of 3D-printed tumor models, offering a significant improvement over traditional preclinical models. These models are engineered to replicate human tumors with unprecedented accuracy, incorporating a diverse array of cells and, prospectively, the tumor vasculature.   Key Advantages: ◾ Complexity: The models feature a comprehensive cellular composition, closely simulating human tissue. ◾ Efficiency: They enable rapid evaluation of therapeutic candidates, accelerating the drug development timeline. ◾ Personalization Potential: These models hold the promise of facilitating more personalized approaches to cancer treatment, based on their ability to mimic individual patient tumors.   Carcinotech's approach not only enhances the precision of preclinical research but also aims to streamline the pathway from laboratory discoveries to clinical applications, embodying a significant stride towards more personalized and effective cancer therapies.   #CancerResearch #MedicalInnovation #3DPrinting #Oncology #Biotechnology #Tumor

Exciting developments in targeted cancer therapy by Dr. Francis M. Barnie! ICT10336, a novel hypoxia-responsive prodrug of ATR inhibitor AZD6738, shows promising preclinical results. It specifically releases AZD6738 in hypoxic conditions, inhibiting ATR activation and selectively killing cancer cells. ICT10336 is less toxic to normal tissues and effectively penetrates 3D tumour models. For more news, please find us here https://lnkd.in/diBi-RN #CancerResearch #TargetedTherapy #Oncology #PharmaInnovation

FERROPTOSIS INDUCERS: A NEW FRONTIER IN CANCER THERAPY Ferroptosis represents a non-apoptotic form of programmed cell death characterized by iron-dependent lipid peroxidation. This cell death modality not only facilitates the direct elimination of cancer cells, but also enhances their susceptibility to other pharmacological anti-cancer agents. The burgeoning interest in ferroptosis has been driven by a growing body of evidence that underscores the efficiency and minimal toxicity of ferroptosis inducers. Traditional inducers, such as erastin and RSL3 have shown substantial promise in clinical applications due to their potent therapeutic effects. Their significant potential of these inducers has spurred the development of a variety of small molecule ferroptosis inducers. This review by W. Ma et al., in Bioorganic Chemistry, scrutinizes the latest progress in small molecule ferroptosis inducers and nano drug delivery systems geared towards ferroptosis sensitization. Furthermore, it delineated the prospective therapeutic advantages and the existing hurdles in the development of ferroptosis inducers for malignant tumor treatment. #ferroptosis #cancer #review https://lnkd.in/dpQEdkyx

Congratulations to our partners KisoJi, who announced today a mAb partnership with Cancer Research UK’s Centre for Drug Development (CDD) who will sponsor, design and deliver a Phase 1/2a clinical trial of KJ-103, in selected TROP2 expressing solid tumours. This is the first non-ADC approach to targeting TROP2, a promising solid tumour target. This mAb, which was humanised by LifeArc, directs macrophage activation and phagocytosis of tumour cells and may bring advantages over TROP2-ADC approaches. https://lnkd.in/eNpsjS6d

Excited to announce preclinical data on new indications for our lead program, AIC100, at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1. “We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types. Advanced stage cervical cancer and NSCLC represent significant unmet medical needs, with patients experiencing poor outcomes and a 5-year survival rate ranging from approximately 10 to 20%,” said Matt Britz, CEO, AffyImmune. “These preclinical data build on the potential for AIC100 to be a first-in-class targeted therapy for ICAM-1-positive solid tumors with significant unmet medical need.” Read the release: https://lnkd.in/ePE-7zxe #AACR24 #oncology

Our Chief Scientific Officer, Dr. Michael Wick, Ph.D., recently authored an article in Today's Clinical Lab titled, “Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models.”   The article dives into how patient-derived xenograft (#PDX) models are reshaping cancer research by providing more accurate, clinically relevant data compared to traditional models. Dr. Wick explores the advantages of PDX models in replicating real patient treatment histories, their use in second- and third-line therapies, and their potential for advancing precision medicine.   Are your PDX models delivering the depth of data and quality you need for your preclinical research? Don’t settle for less when XenoSTART offers a best-in-class approach.   Check out the full article here: https://lnkd.in/eSucBnCp

Be sure to check out our publications in Cancer Discovery that detail the design of AB248 and reviews preclinical data supporting its development as a potentially best-in-class interleukin-2 (IL-2) therapy. #Cancer #Discovery #LightUpWhatMatters

Immuno-Oncology in vivo studies are complex and require meticulous planning and execution. 📕 Read our new blog to enhance your immuno-oncology preclinical research with 5 essential steps, from selecting tumor models to analyzing drug mechanisms. #ImmunoOncology #IO #CancerResearch #Oncologyresearch #cancer #oncology #invivo #exvivo #invivostudy #exvivostudy #syngeneicmodels #humanizedmodels #syngeneic #humanized https://hubs.li/Q02Drkk50